F. V. D. van der Meché

发表

Reliability and responsiveness of a graduated tuning fork in immune mediated polyneuropathies

P. Schmitz, P. V. van Doorn, P. Doorn, 2000, Journal of neurology, neurosurgery, and psychiatry.

Comparison between impairment and disability scales in immune‐mediated polyneuropathies

P. Schmitz, P. V. van Doorn, I. Merkies, 2003, Muscle & nerve.

Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain–Barré syndrome

A. Osterhaus, J. Laman, B. Jacobs, 2000, Neurology.

Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis

W. Hop, R. Hintzen, B. Löwenberg, 2005, Journal of Neurology, Neurosurgery & Psychiatry.

Self reported stressful life events and exacerbations in multiple sclerosis:prospective study

W. Hop, A. Janssens, R. Hintzen, 2003, BMJ : British Medical Journal.

Expectations of wheelchair‐dependency in recently diagnosed patients with multiple sclerosis and their partners

A. Janssens, J. Passchier, J. D. de Boer, 2003, European journal of neurology.

Campylobacter jejuni infections and anti‐GM1 antibodies in guillain‐barré syndrome

L. Visser, P. Schmitz, H. Hooijkaas, 1996, Annals of neurology.

Prospective study on the relationship between infections and multiple sclerosis exacerbations.

W. Hop, R. Hintzen, J. Laman, 2002, Brain : a journal of neurology.

Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies

P. V. van Doorn, P. Schmitz, I. Merkies, 2000, Neurology.

The spectrum of antecedent infections in Guillain-Barré syndrome

P. Schmitz, B. Jacobs, P. Doorn, 1998, Neurology.

Decreased electrical excitability of peripheral nerves in demyelinating polyneuropathies.

J. Meulstee, P. V. van Doorn, F. V. D. van der Meché, 1997, Journal of neurology, neurosurgery, and psychiatry.

Guillain-Barré Syndrome- and Miller Fisher Syndrome-Associated Campylobacter jejuni Lipopolysaccharides Induce Anti-GM1 and Anti-GQ1b Antibodies in Rabbits

H. Endtz, J. Laman, B. Jacobs, 2001, Infection and Immunity.

Campylobacter jejuni lipopolysaccharides from Guillain-Barré syndrome patients induce IgG anti-GM1 antibodies in rabbits.

H. Endtz, J. Laman, B. Jacobs, 2000, Journal of neuroimmunology.

Anti‐GM1 IgG antibodies and campylobacter bacteria in Guillain‐Barré syndrome: Evidence of molecular mimicry

B. Jacobs, F. V. D. van der Meché, J. R. Bänffer, 1995, Annals of neurology.

Comparative study of preceding Campylobacter jejuni infection in Guillain-Barré syndrome in Japan and The Netherlands

K. Hirata, N. Yuki, M. Koga, 2001, Journal of neurology, neurosurgery, and psychiatry.

Serum anti‐GQ1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome

H. Achtereekte, H. Endtz, B. Jacobs, 1995, Annals of neurology.

Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barré syndrome.

B. Jacobs, P. V. van Doorn, A. P. Tio‐Gillen, 1997, Journal of neurology, neurosurgery, and psychiatry.

Long-term sensory deficit after Guillain-Barré syndrome

P. Schmitz, A. de Jager, F. V. D. van der Meché, 2001, Journal of Neurology.

Mild forms of Guillain-Barré syndrome in an epidemiologic survey in the Netherlands

P. Schmitz, P. V. van Doorn, R. van Koningsveld, 2000, Neurology.

Epstein-Barr virus and disease activity in multiple sclerosis

W. Hop, A. Osterhaus, R. Hintzen, 2005, Journal of Neurology, Neurosurgery & Psychiatry.

Psychometric evaluation of a new handicap scale in immune‐mediated polyneuropathies

J. Samijn, P. V. van Doorn, P. Schmitz, 2002, Muscle & nerve.

Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy

P. Schmitz, P. V. van Doorn, P. Schmitz, 1998, Journal of neurology, neurosurgery, and psychiatry.

Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies

P. Schmitz, J. Samijn, P. V. van Doorn, 2002, Journal of neurology, neurosurgery, and psychiatry.

Fatigue in immune-mediated polyneuropathies

P. Schmitz, J. Samijn, P. V. van Doorn, 1999, Neurology.

Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates.

M. Daha, H. Willison, P. Molenaar, 1999, Annals of neurology.

Risk factors for the development of polyneuropathy and myopathy in critically ill patients

L. Visser, P. Schmitz, F. Verheul, 2001, Critical care medicine.

Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain‐Barré syndrome

P. Schmitz, F. V. D. van der Meché, R. P. Kleyweg, 1991, Muscle & nerve.

High-dose intravenous immunoglobulin therapy for myasthenia gravis

P. V. van Doorn, J. Jongen, F. Meché, 1987, Journal of Neurology.

Long‐Term Results of Uvulopalatopharyngoplasty for Obstructive Sleep Apnea Syndrome

P. Schmitz, R. Poublon, F. V. D. van der Meché, 2000, The Laryngoscope.

Connecting impairment, disability, and handicap in immune mediated polyneuropathies

P. Schmitz, J. Samijn, P. V. van Doorn, 2003, Journal of neurology, neurosurgery, and psychiatry.

Chronic motor neuropathies: response to interferon-β1a after failure of conventional therapies

J. Meulstee, P. Schmitz, P. V. van Doorn, 1999, Journal of neurology, neurosurgery, and psychiatry.

Liver function disturbances in Guillain-Barre syndrome

F. V. D. van der Meché, P. Oomes, R. Kleyweg, 1996, Neurology.

Dietary antioxidants and Parkinson disease. The Rotterdam Study.

A. Hofman, M. Breteler, L. Launer, 1997, Archives of neurology.

Prediction of anxiety and distress following diagnosis of multiple sclerosis: a two-year longitudinal study

C. Polman, A. Janssens, J. Passchier, 2006, Multiple sclerosis.

Miller Fisher anti‐GQ1b antibodies: α‐Latrotoxin–like effects on motor end plates

M. Daha, H. Willison, P. Molenaar, 1999 .

Prevalence of Parkinson's disease in the elderly

A Hofman, D E Grobbee, A. Hofman, 1995, Neurology.

Amantadine for treatment of fatigue in Guillain-Barré syndrome: a randomised, double blind, placebo controlled, crossover trial

P. Schmitz, B. Jacobs, P. V. van Doorn, 2005, Journal of Neurology, Neurosurgery & Psychiatry.

Treatment of Guillain‐Barré syndrome with high‐dose gammaglobulin

J. Meulstee, R. P. Kleyweg, F. V. D. van der Meché, 1988, Neurology.

Psychosocial dysfunction in the first year after Guillain–Barré syndrome

T. Suurmeijer, A. de Jager, W. Kuijer, 2010, Muscle & nerve.

How Guillain–Barré patients experience their functioning after 1 year

T. Suurmeijer, A. de Jager, F. V. D. van der Meché, 2005, Acta neurologica Scandinavica.

Infections and course of disease in mild forms of Guillain–Barré syndrome

A. Osterhaus, J. Groen, P. Schmitz, 2002, Neurology.

Residual health status after Guillain-Barré syndrome.

A. de Jager, F. V. D. van der Meché, H. Jacobs, 1997, Journal of neurology, neurosurgery, and psychiatry.

Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange

J. Meulstee, P. Schmitz, L. Visser, 1999, Neurology.

Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome

P. Schmitz, A. de Jager, F. V. D. van der Meché, 1999, Neurology.

Perception of prognostic risk in patients with multiple sclerosis: the relationship with anxiety, depression, and disease-related distress.

Jan Passchier, A Cecile J W Janssens, A. Janssens, 2004, Journal of clinical epidemiology.

A nxiety and depression influence the relation between disability status and quality of life in multiple sclerosis

A. Janssens, J. Passchier, J. D. de Boer, 2003, Multiple sclerosis.

Rapidly progressive, predominantly motor Guillain-Barré syndrome with anti-GalNAc-GD1a antibodies

N. Yuki, M. Koga, B. Jacobs, 1999, Neurology.

Clinical features and response to treatment in Guillain‐Barré syndrome associated with antibodies to GM1b ganglioside

K. Hirata, N. Yuki, M. Koga, 2000, Annals of neurology.

Quality of life complements traditional outcome measures in immune-mediated polyneuropathies

P. Schmitz, J. Samijn, P. V. van Doorn, 2002, Neurology.

Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group.

P. Schmitz, J. Samijn, P. V. van Doorn, 1999, Neurology.

Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome.

H. Endtz, B. Jacobs, P. V. van Doorn, 1997, The Journal of infectious diseases.

A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group.

P. Schmitz, F. G. Meché, P. Schmitz, 1992, The New England journal of medicine.

Axonal damage in Guillain‐Barré syndrome

J. Meulstee, R. P. Kleyweg, F. van der Meché, 1991, Muscle & nerve.

Are Immunoglobulins Superior to Plasma Exchange in the Guillain-Barré Syndrome?

J. Meulstee, P. Schmitz, P. Schmitz, 1991 .

Cross-reactive anti-galactocerebroside antibodies and Mycoplasma pneumoniae infections in Guillain–Barré syndrome

A. Osterhaus, J. Groen, B. Jacobs, 2002, Journal of Neuroimmunology.

Changes in referral pattern and its effect on outcome in patients with Guillain–Barré syndrome

P. Schmitz, P. Schmitz, P. V. van Doorn, 2001, Neurology.

Uvulopalatopharyngoplasty for the obstructive sleep apnoea syndrome: value of polysomnography, Mueller manoeuvre and cephalometry in predicting surgical outcome.

H. Boot, P. Schmitz, F. V. D. van der Meché, 1997, Clinical otolaryngology and allied sciences.

The current place of high‐dose immunoglobulins in the treatment of neuromuscular disorders

P. V. van Doorn, F. V. D. van der Meché, 1997, Muscle & nerve.